ClinicalTrials.gg
WithdrawnNCT02462707Updated Oct 7, 2015

A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors

A Phase 1 interventional study of PF-03084014 in Advanced Solid Tumors, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-07.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the recommended Phase 2 dose for PF-03084014 single-agent administration in Japanese patients with advanced solid tumors. Pharmacokinetics and the overall safety profile of PF-03084014 will also be evaluated.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of advanced solid tumors that is resistant to standard therapy or for which no standard therapy is available.
  • Age ≥18 years.
  • Performance Status (PS) must be 0 or 1.
  • Adequate Bone Marrow Function
  • Adequate Renal Function
  • Adequate Liver Function
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤1

Exclusion criteria

Exclusion Criteria:

  • Patients with known
  • Major surgery within 4 weeks of starting study treatment
  • Radiation therapy within 2 weeks of starting study treatment
  • Systemic anti cancer therapy within 2 weeks (4 weeks for antibody) of starting study treatment
  • Previous high dose chemotherapy requiring stem cell rescue
  • Prior irradiation to >25% of the bone marrow
  • Prior treatment with a Notch signal inhibitor
  • Known malabsorption syndrome or other condition that may impair absorption of study medication
  • Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or symptomatic pulmonary embolism
  • Current use or anticipated need for known strong and/or moderate inhibitors
  • Current use or anticipated need for known strong CYP3A4 inducers
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    PF-03084014

    Drug: PF-03084014

Interventions

  • gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule

06

What researchers measure

Primary outcomes

  1. First-cycle Dose Limiting Toxicities

    Time frame: during the first 28 days from the first dose

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  2. QTc interval

    Time frame: from the first dose to the last dose

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  4. Area Under the Curve from Time Zero to end of dosing interval (AUCtau)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  5. Plasma Decay Half-Life (t1/2)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  6. Apparent Oral Clearance (CL/F)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  7. Apparent Volume of Distribution at steady state (Vss/F)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  8. Minimum Observed Plasma Trough Concentration (Cmin)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  9. Average Serum Concentration at steady state (Cav)

    Time frame: 0, 0.5, 1, 2, 4, 8, 24, 48, 96, 120 hours post-dose

  10. Accumulation Ratio (Rac)

    Time frame: 0, 0.5, 1, 2, 4, 8 hours post-dose on Day 1 and Day 21

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jun 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2015
First posted
Jun 4, 2015
Start
Jul 2015
Primary completionEst.
Jun 2016
CompletionEst.
Oct 2016
Last update
Oct 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02462707
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 4, 2015
Start date
Jul 2015
Primary completion
Jun 2016 (estimated)
Completion
Oct 2016 (estimated)
Last update
Oct 7, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion